Breast Cancer : Basic and Clinical Research最新文献

{"title":"Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates.","authors":"Daniel González-Hurtado,&nbsp;Sergio Rivero,&nbsp;Juan Carlos Samamé Pérez-Vargas,&nbsp;Fernando E Petracci","doi":"10.1177/11782234231192780","DOIUrl":"https://doi.org/10.1177/11782234231192780","url":null,"abstract":"<p><p>Prognostic and predictive factors for early and late distant distance recurrence risk in estrogen-receptor positive and HER2-receptor negative early breast cancer are well known, but not all these variables work equally for the prediction. The following are the most widely accepted variables for categorizing risk levels: clinic-pathologic features (tumor size, lymph node involvement, histological grade, age, menopausal status, Ki-67 expression, estrogen, and progesterone expression), primary systemic treatment response (pathologic response and/or Ki-67 downstaging), and gene expression signatures stratification. Treatment guidelines from cancer societies and collaborative groups, online predict-tools, real-world data and experts' opinion recommends different adjuvant strategies (chemotherapy, endocrine therapy, ovarian suppression, olaparib, or abemaciclib) depending on the low (< 10%), intermediate (10%-20%) or high-risk of distance recurrence at least in the first 5 years. Multiple randomized prospective trials were updated in 2022, that evidence allow us to perform a stratification of risk in pre- and postmenopausal women with estrogen-receptor positive and HER2-receptor negative early breast cancer based on a combination of clinic-pathologic features and genomic assays and guide the adjuvant systemic treatment recommendation for those with high risk.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231192780"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/1c/10.1177_11782234231192780.PMC10450458.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>TP53</i> Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease.","authors":"Shin Takahashi,&nbsp;Keiju Sasaki,&nbsp;Chikashi Ishioka","doi":"10.1177/11782234231167655","DOIUrl":"https://doi.org/10.1177/11782234231167655","url":null,"abstract":"<p><strong>Background: </strong>The <i>TP53</i> signature that predicts the mutation status of <i>TP53</i> has been shown to be a prognostic factor and predictor of neoadjuvant chemotherapy (NAC) response.</p><p><strong>Objectives: </strong>The current study sought to investigate the utility of the <i>TP53</i> signature for predicting pathological complete response (pCR) and its prognostic significance among patients with residual disease (RD).</p><p><strong>Design: </strong>The study followed a retrospective cohort study design.</p><p><strong>Methods: </strong>Patients with T1-3/N0-1 from a cohort of those with HER2-negative breast cancer who received NAC were selected. Ability to predict pCR was evaluated using odds ratio, positive and negative predictive values, sensitivity, and specificity. Prognostic factors in the RD group were explored using the Cox proportional hazards model with distant recurrence-free survival (DRFS). Four independent cohorts were used for validation.</p><p><strong>Results: </strong>A total of 333 eligible patients were classified into the <i>TP53</i> mutant signature (n = 154) and wild-type signature (n = 179). Among the molecular and pathological factors, the <i>TP53</i> signature had the highest predictive power for pCR. In 4 independent cohorts (n = 151, 85, 104, and 67, respectively), pCR rate in <i>TP53</i> mutant signature group was significantly higher than that in the wild-type group. Univariate and multivariate analyses on DRFS in the RD group identified the <i>TP53</i> signature and nodal status as independent prognostic factors, with the former having a better hazard ratio than the latter. After comparing DRFS between 3 groups (pCR, RD/<i>TP53</i> wild-type signature, and RD/<i>TP53</i> mutant signature groups), the RD/<i>TP53</i> mutant signature group showed significantly worse prognosis compared with others. The RD/<i>TP53</i> wild-type signature group did not exhibit inferior DRFS compared with the pCR group.</p><p><strong>Conclusion: </strong>Our results showed that the <i>TP53</i> mutant signature can predict pCR and that combining pathological response and <i>TP53</i> mutant signature allows for the identification of subgroups with truly poor prognosis.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231167655"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/26/10.1177_11782234231167655.PMC10170595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10290147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iopromide for Contrast-Enhanced Mammography: A Systemic Review and Meta-Analysis of Pertinent Literature.","authors":"Jan Endrikat,&nbsp;Hassan Khater,&nbsp;Alexander Dp Boreham,&nbsp;Sabine Fritze,&nbsp;Carsten Schwenke,&nbsp;Aasia Bhatti,&nbsp;Zuzana Jirakova Trnkova,&nbsp;Peter Seidensticker","doi":"10.1177/11782234231189467","DOIUrl":"https://doi.org/10.1177/11782234231189467","url":null,"abstract":"<p><strong>Background: </strong>Contrast-enhanced mammography (CEM) is an emerging breast imaging modality. Clinical data is scarce.</p><p><strong>Objectives: </strong>To summarize clinical evidence on the use of iopromide in CEM for the detection or by systematically analyzing the available literature on efficacy and safety.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Data sources and methods: </strong>Iopromide-specific publications reporting its use in CEM were identified by a systematic search within Bayer's Product Literature Information (PLI) database and by levering a recent review publication. The literature search in PLI was performed up to January 2023. The confirmatory-supporting review publication was based on a MEDLINE/EMBASE + full text search for publications issued between September 2003 and January 2019. Relevant literature was selected based on pre-defined criteria by 2 reviewers. The comparison of CEM vs traditional mammography (XRM) was performed on published results of sensitivity and specificity. Differences in diagnostic parameters were assessed within a meta-analysis.</p><p><strong>Results: </strong>Literature search: A total of 31 studies were identified reporting data on 5194 patients. Thereof, 19 studies on efficacy and 3 studies on safety. Efficacy: in 11 studies comparing iopromide CEM vs XRM, sensitivity was up to 43% higher (range 1%-43%) for CEM. Differences in specificity were found to be in a range of -4% to 46% for CEM compared with XRM. The overall gain in sensitivity for CEM vs XRM was 7% (95% CI [4%, 11%]) with no statistically significant loss in specificity in any study assessed. In most studies, accuracy, positive predictive value, and negative predictive value were found to be in favor of CEM. In 2 studies comparing CEM with breast magnetic resonance imaging (bMRI), both imaging modalities performed either equally well or CEM tended to show better results with respect to sensitivity and specificity. Safety: eight cases of iopromide-related adverse drug reactions were reported in 1022 patients (0.8%).</p><p><strong>Conclusions: </strong>Pertinent literature provides evidence for clinical utility of iopromide in CEM for the detection or confirmation of breast cancer. The overall gain in sensitivity for iopromide CEM vs XRM was 7% with no statistically significant loss in specificity.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231189467"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/69/10.1177_11782234231189467.PMC10433886.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10651368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Educational Intervention Based on Theory of Planned Behavior (TPB) on Doing Breast Self-examination in a Sample of Iranian Women.","authors":"Ali Khani Jeihooni,&nbsp;Zahra Sadat Moayedi,&nbsp;Victoria Momenabadi,&nbsp;Farzaneh Ghalegolab,&nbsp;Pooyan Afzali Harsini","doi":"10.1177/11782234221145417","DOIUrl":"https://doi.org/10.1177/11782234221145417","url":null,"abstract":"<p><strong>Background: </strong>Breast self-examination (BSE) is an important part of health care for all women in every stage of life. This study aimed to investigate the effect of theory of planned behavior (TPB) on doing BSE in a sample of Iranian women.</p><p><strong>Methods: </strong>A cross-sectional study was carried out to examine the factors affecting the BSE in 400 women. Then, a quasi-experimental study was conducted on 200 subjects (100 in experimental group and 100 in control group). The educational intervention for the experimental group consisted of 8 training sessions. A questionnaire including demographic characteristics, knowledge, and constructs of TPB was used to measure BSE performance before and 6 months after the intervention. Constructs of attitude, subjective norms, and perceived behavioral control predicted the intention to do the BSE.</p><p><strong>Results: </strong>The mean age of the subjects was 31.65 ± 7.59 years. The studied variables predicted 38.7% of behavioral intention (<i>P</i> < .001, odds ratio = 0.387). Six months after the intervention, the experimental group showed a significant increase in the knowledge, attitude, perceived behavioral control, subjective norms, intention, and BSE performance compared with the control group (<i>P</i> < .001).</p><p><strong>Conclusions: </strong>This study showed that educational intervention based on the TPB was effective in promoting breast cancer screening behavior such as BSE. Therefore, it is suggested that health educators and health care planners use educational texts based on these constructs of TPB to increase their influence on individuals via screening behavior for breast cancer.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234221145417"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/fd/10.1177_11782234221145417.PMC9884953.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10696623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Potential Diagnostic Role of the Lnc-MIAT, miR-29a-3p, and FOXO3a ceRNA Networks as Noninvasive Circulatory Bioindicator in Ductal Carcinoma Breast Cancer.","authors":"Shokufeh Razi,&nbsp;Hossein Mozdarani,&nbsp;Roudabeh Behzadi Andouhjerdi","doi":"10.1177/11782234231184378","DOIUrl":"https://doi.org/10.1177/11782234231184378","url":null,"abstract":"<p><strong>Background: </strong>Over the last few decades, tremendous progress has been achieved in the early detection and treatment of breast cancer (BC). However, the prognosis remains unsatisfactory, and the underlying processes of carcinogenesis are still unclear. The purpose of this research was to find out the relationship between myocardial infarction-associated transcript (<i>MIAT</i>), <i>FOXO3a</i>, and <i>miRNA29a-3p</i> and evaluated the expression levels in patients compare with control and their potential as a noninvasive bioindicator in whole blood in BC.</p><p><strong>Methods: </strong>Whole blood and BC tissue are taken from patients before radiotherapy and chemotherapy. Total RNA was extracted from BC tissue and whole blood to synthesize complementary DNA (cDNA). The expression of <i>MIAT, FOXO3a</i>, and <i>miRNA29a</i>-<i>3p</i> was analyzed by the quantitative reverse transcription-polymerase chain reaction (RT-qPCR) method and the sensitivity and specificity of them were determined by the receiver operating characteristic (ROC) curve. Bioinformatics analysis was used to understand the connections between <i>MIAT, FOXO3a</i>, and <i>miRNA29a</i>-<i>3p</i> in human BC to develop a ceRNA (competitive endogenous RNA) network.</p><p><strong>Results: </strong>We identified that in ductal carcinoma BC tissue and whole blood, <i>MIAT</i> and <i>FOXO3a</i> were more highly expressed, whereas <i>miRNA29a</i>-<i>3p</i> was lower compared with those in nontumor samples. There was a positive correlation between the expression levels of <i>MIAT, FOXO3a</i>, and <i>miRNA29a</i>-<i>3p</i> in BC tissues and whole blood. Our results also proposed <i>miRNA29a</i>-<i>3p</i> as a common target between <i>MIAT</i> and <i>FOXO3a</i>, and we showed them as a ceRNA network.</p><p><strong>Conclusions: </strong>This is the first study that indicates <i>MIAT, FOXO3a</i>, and <i>miRNA29a</i>-<i>3p</i> as a ceRNA network, and their expression was analyzed in both BC tissue and whole blood. As a preliminary assessment, our findings indicate that combined levels of <i>MIAT, FOXO3a</i>, and <i>miR29a</i>-<i>3p</i> may be considered as potential diagnostic bioindicator for BC.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231184378"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/e5/10.1177_11782234231184378.PMC10331106.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10300877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Side Effects and Its Management in Adjuvant Endocrine Therapy for Breast Cancer: A Matter of Communication and Counseling.","authors":"Aina Johnsson,&nbsp;Kerstin Fugl-Meyer,&nbsp;Pal Bordas,&nbsp;Janet Åhman,&nbsp;Anna Von Wachenfeldt","doi":"10.1177/11782234221145440","DOIUrl":"https://doi.org/10.1177/11782234221145440","url":null,"abstract":"<p><strong>Objective: </strong>Women with a newly diagnosed hormone receptor-positive breast cancer are offered adjuvant endocrine therapy (AET). Although the treatment reduces the risk of relapse and death not all women are adherent to it. Many factors, including the therapy's menopausal side effects, can adversely affect adherence to the treatment. This study explores the extent to which women treated with AET perceived that health care providers addressed their side effects.</p><p><strong>Methods: </strong>Ten focus groups were set up, containing between four to nine women. In total, 58 women participated in the study-45 from the Stockholm metropolitan region and 13 from the scarcely populated Norrbotten region. The interviews were analyzed using qualitative content analysis with an inductive approach.</p><p><strong>Results: </strong>The women were usually satisfied with the care they received from the health care providers. However, their experiences were more complex when it came to their satisfaction with the care in terms of the menopausal side effects of therapy, sexuality in particular. The participants reported that their healthcare providers rarely asked about sex life-related side effects of the treatment.</p><p><strong>Conclusions: </strong>Health care providers need to communicate and consult about issues related to their patients' sex lives following their breast cancer diagnosis and during their treatment.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234221145440"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10623248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Breast Cancer Progression after Treatment in the Western Region of Saudi Arabia.","authors":"Majed Ramadan,&nbsp;Rwiah Alsiary,&nbsp;Noor Alsaadoun,&nbsp;Noara Alhusseini,&nbsp;Muhammad Raihan Sajid,&nbsp;Noor Mohamed Hamed,&nbsp;Tarek Ziad Arabi,&nbsp;Belal Nedal Sabbah","doi":"10.1177/11782234231158270","DOIUrl":"https://doi.org/10.1177/11782234231158270","url":null,"abstract":"<p><strong>Background: </strong>The risk of breast cancer progression is one of the most difficult factors to predict as it is studied in different populations, patient groups, or time frames, resulting in conflicting estimates of incidence rates reported in the literature. The purpose of this study is to identify predictive factors for breast cancer recurrences in a sample of the Middle Eastern population.</p><p><strong>Methodology: </strong>A cohort retrospective study included all eligible breast cancer patients at the National Guard Health Affairs (NGHA) Hospital in Jeddah, Western region, from 2015 to 2021. Our primary outcome was the progression status of the patients; we adjusted for demographic, clinical, and molecule characteristics of the population. From 2015 to 2021, there were 319 patients diagnosed with breast cancer. Multiple logistic regression analysis was used to estimate predictors of breast cancer progression.</p><p><strong>Results: </strong>One of five breast cancer patients had breast cancer progression (20.83%), while 66.15% of the progression patients were between the ages of 41-65. In multivariate analysis, age, progesterone receptor (PR), family history, and tumor size were significant predictors of breast cancer progression. The age group of 20-40 years was a protective predictor of breast cancer progression, patients in the young age group were less likely to be diagnosed with progression (OR = 0.35; CI = 0.15, 0.81). While negative PRs and tumor size greater than 2 cm were significant predictor factors of breast cancer progression (OR = 2.07; CI = 1.09, 3.91, OR = 2.02; CI = 1.9, 3.78).</p><p><strong>Conclusion: </strong>Although the effect of young age as a protective factor for the progression of breast cancer remains controversial, our study revealed that patients between 41 and 60 years of age had a higher rate of progression. Future larger prospective studies are needed to delineate the role of age and PR hormone receptors in determining the best treatment options for women with breast cancer in the Saudi population.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231158270"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/af/10.1177_11782234231158270.PMC10061810.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9296643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer.","authors":"Matthew G Davey,&nbsp;Michael J Kerin","doi":"10.1177/11782234221145409","DOIUrl":"https://doi.org/10.1177/11782234221145409","url":null,"abstract":"outcomes for premenopausal women who develop metastatic LABC","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234221145409"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/c7/10.1177_11782234221145409.PMC9841871.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10541946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.","authors":"Thitiya Dejthevaporn,&nbsp;Panchanin Patanayindee","doi":"10.1177/11782234231186869","DOIUrl":"https://doi.org/10.1177/11782234231186869","url":null,"abstract":"<p><strong>Background: </strong>The risk of late distant recurrence (LDR) of estrogen receptor (ER)-positive breast cancer continues even after 5 years of endocrine treatment. Clinical Treatment Score after 5 years (CTS5) was developed and validated as a tool to assess the risk of LDR using data from Tamoxifen, Arimidex Alone or in Combinations (ATAC) and Breast International Group 1-98 (BIG1-98) trials. This study aimed to externally validate CTS5 in a real-world cohort of patients treated at an academic center in Thailand.</p><p><strong>Methods: </strong>The study was a retrospective analytical research study of early-stage, ER-positive breast cancer patients. The primary endpoint was LDR. The risk of LDR was determined using the CTS5 calculator. Cox regression model and Kaplan-Meier survival analysis were applied for prognostic validation of CTS5. Calibration was performed by comparing observed LDR to expected LDR using the Hosmer-Lemeshow (H-L) test.</p><p><strong>Results: </strong>A total of 323 women were included with a median follow-up period of 11.6 years. The rate of LDR was 10.8%. The CTS5 was prognostic for LDR. C-index of the area under the ROC curve was 0.672. There was no significant difference between actual and expected numbers of LDR with an observed (O) LDR events to expected (E) number of LDR events ratio of 0.99 (0.86-1.12) (H-L <i>P</i> = .79) indicating a proper calibration in this cohort.</p><p><strong>Conclusions: </strong>Our study validated that CTS5 is accurate in predicting the risk of LDR in ER-positive breast cancer cases in Thai patients. Its performance seemed to be better in postmenopausal patients. CTS5 could be applied in routine clinical practice to improve decisions regarding prolonged endocrine therapy, particularly in resource-limited countries where molecular profiling are inaccessible.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231186869"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/53/10.1177_11782234231186869.PMC10392218.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9932995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marking Techniques for Targeted Axillary Dissection Among Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy.","authors":"Inês Gante,&nbsp;João Pedro Maldonado,&nbsp;Margarida Figueiredo Dias","doi":"10.1177/11782234231176159","DOIUrl":"https://doi.org/10.1177/11782234231176159","url":null,"abstract":"<p><p>Invasive breast cancer with axillary lymph node (LN) invasion is a continuing problem worldwide. The morbidity associated with axillary LN dissection along with the high rate of nodal downstaging after neoadjuvant chemotherapy (NACT) made the standard treatment shift towards less invasive surgery. Sentinel lymph node biopsy (SLNB) after NACT is associated with high false-negative rates (13%-14%). To overcome this problem, it was concluded that the positive nodes should first be indicated with image-detectable markers and then removed together with SLNB: targeted axillary dissection (TAD). This review aims to describe and evaluate the different marking techniques for TAD in patients with node-positive breast cancer treated with NACT, namely: clip placement and guidewire localization; clip placement and 125I-labelled radioactive seed localization; clip placement and skin mark; clip placement and intraoperative ultrasound; tattooing with a sterile black carbon suspension; magnetic seeds; radar and infrared light technology localization. Targeted axillary dissection techniques have shown false-negative rates below 9% and identification rates above 95%. The most studied technique is guidewire localization, as it is also the oldest one. However, according to data gathered from this review, some newer techniques have shown to be very promising due to their statistical results and management factors.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231176159"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/48/10.1177_11782234231176159.PMC10226338.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9553583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}